Literature DB >> 29907

Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

D J Greenblatt, K Franke, R I Shader.   

Abstract

This paper describes a rapid and sensitive method for analysis of lorazepam and its glucuronide metabolite in plasma and urine following therapeutic doses of lorazepam in humans. After addition of the structurally related benzodiazepine derivative, oxazepam, as the internal standard, 1-ml samples of plasma or urine are extracted twice at neutral pH with benzene (containing 1.5% isoamyl alcohol). The combined extracts are evaporated to dryness, reconstituted, and subjected to gas chromatographic analysis using a 3% OV-17 column and an electron-capture detector. Lorazepam glucuronide in urine is similarly analyzed following enzymatic cleavage with Glusulase. The sensitivity limits are 1--3 ng of analyzed following enzymatic cleavage with Glusulase. The sensitivity limits are 1--3 ng of lorazepam per ml of original sample, and the variability of identical samples is 5% or less. The applicability of the method to pharmacokinetic studies of lorazepam is demonstrated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 29907

Source DB:  PubMed          Journal:  J Chromatogr


  34 in total

1.  Chronic treatment with Ro 15-1788 distinguishes between its benzodiazepine antagonist, agonist and inverse agonist properties.

Authors:  S E File; J Dingemanse; H L Friedman; D J Greenblatt
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of benzodiazepines. I: Lorazepam.

Authors:  S K Gupta; E H Ellinwood; A M Nikaido; D G Heatherly
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

3.  Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam.

Authors:  E H Ellinwood; D G Heatherly; A M Nikaido; T D Bjornsson; C Kilts
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

4.  Benzodiazepine receptors mediate regional blood flow changes in the living human brain.

Authors:  E Matthew; P Andreason; K Pettigrew; R E Carson; P Herscovitch; R Cohen; C King; C E Johanson; D J Greenblatt; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

5.  Recovery from lorazepam tolerance and the effects of a benzodiazepine antagonist (RO 15-1788) on the development of tolerance.

Authors:  S E File
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers.

Authors:  A Patat; M C Perault; B Vandel; N Ulliac; I Zieleniuk; P Rosenzweig
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

7.  A study of conjugation and drug elimination in the human neonate.

Authors:  A J Cummings; A G Whitelaw
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of oxazepam and lorazepam.

Authors:  D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

9.  Effect of maternal lorazepam on the neonate.

Authors:  A G Whitelaw; A J Cummings; I R McFadyen
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-04

10.  Pharmacokinetic and pharmacodynamic interaction between the antidepressant tianeptine and oxazepam at steady-state.

Authors:  S Toon; B L Holt; S J Langley; F G Mullins; M Rowland; M S Halliday; C Salvadori; B Delalleau
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.